Our laboratories have a long-standing interest in immune tolerance in transplantation, with a particular focus on regulatory T cells (Tregs). While Tregs expressing Foxp3 are required for normal immune homeostasis increasing data suggests that this lineage of cells may be unstable (e.g., as a result for example of inadequate IL-2, TCR and CD28 stimulation, or due to exposure to inflammatory cytokines), meaning that Tregs can revert/convert to effector T cells and thus contribute to loss of tolerance to self or to allografts. One of the key pathways controlling lymphocyte lineage specification and responsiveness is the PI3K pathway, which can be activated via CD28 and the IL-2R. While PI3K is essential for conventional T cell responses, over activation of the PI3K pathway dramatically inhibits Treg development. The primary regulator of PI3K activity in T cells is the lipid phosphatase PTEN (phosphatase and tensin homolog on chromosome 10). To investigate how PI3K controls Tregs, we created mice with PTEN deleted specifically in Tregs by breeding mice with a PTENfl/fl allele with Foxp3-YFP-Cre knock-in animals to generate PTEN-DTreg mice. Surprisingly, although these mice have elevated numbers of Tregs, a high proportion of those cells are CD25- and CD62Llo, and the animals are susceptible to induced autoimmunity and ultimately develop a severe polyclonal lymphoproliferative disorder. Interestingly, preliminary studies suggest that PTEN-deficient Tregs may have profound metabolic alterations, including over-reliance on glycolysis (vs. oxidative metabolism) for energy. Moreover, inhibition of glycolysis restores CD25 levels to normal. This has led us to formulate the hypothesis that PI3K activity induced via inflammation may disrupt Treg homeostasis due to reduced cytokine receptor expression, altered metabolism and apparent loss of regulatory capacity. Our goals are to determine how PI3K in Tregs controls Treg homeostasis and whether drug targeting of the PI3K pathway can stabilize Tregs. To do so, we have three aims.
In Aim #1, we will use fate mapping mice to examine how PTEN loss alters Treg stability and function under homeostatic conditions, and in a well characterized model of autoimmunity.
In Aim #2, we will determine the mechanism by which PI3K controls CD25 expression, examine how loss of PTEN alters Treg metabolism, define what role these changes play in Treg homeostasis and stability, and identify drugs which modulate metabolism that can be used to stabilize Tregs in vitro.
In Aim #3, we will apply these findings, and pharmacologic manipulation to transplantation models, including a humanized mouse model, to develop means to optimize Treg stability and function. Together, these studies will yield new insights into Treg signaling pathways and provide potential therapeutics strategies to enhance immune tolerance.

Public Health Relevance

A specific class of T lymphocytes, known as regulatory T cells, are important for controlling the rejection of organ and tissue transplants and for preventing autoimmune disease. The research proposed will examine how a cell signaling pathway, called the PI3K pathway, regulates the development and function of regulatory T cells.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Program Projects (P01)
Project #
Application #
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Program Officer
Schwartz, Lisa
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Massachusetts General Hospital
United States
Zip Code
Newton, Ryan H; Shrestha, Sharad; Sullivan, Jenna M et al. (2018) Maintenance of CD4 T cell fitness through regulation of Foxo1. Nat Immunol 19:838-848
Hotta, Kiyohiko; Oura, Tetsu; Dehnadi, Abbas et al. (2018) Long-term Nonhuman Primate Renal Allograft Survival Without Ongoing Immunosuppression in Recipients of Delayed Donor Bone Marrow Transplantation. Transplantation 102:e128-e136
Robinson, Kortney A; Orent, William; Madsen, Joren C et al. (2018) Maintaining T cell tolerance of alloantigens: Lessons from animal studies. Am J Transplant 18:1843-1856
Sasaki, Hajime; Oura, Tetsu; Spitzer, Thomas R et al. (2018) Preclinical and clinical studies for transplant tolerance via the mixed chimerism approach. Hum Immunol 79:258-265
Tanimine, Naoki; Turka, Laurence A; Priyadharshini, Bhavana (2018) Navigating T-Cell Immunometabolism in Transplantation. Transplantation 102:230-239
Michel, S G; Madariaga, M L L; LaMuraglia 2nd, G M et al. (2018) The effects of brain death and ischemia on tolerance induction are organ-specific. Am J Transplant 18:1262-1269
Smith, R N; Adam, B A; Rosales, I A et al. (2018) RNA expression profiling of renal allografts in a nonhuman primate identifies variation in NK and endothelial gene expression. Am J Transplant 18:1340-1350
Chatterjee, Debanjana; Moore, Carolina; Gao, Baoshan et al. (2018) Prevalence of polyreactive innate clones among graft--infiltrating B cells in human cardiac allograft vasculopathy. J Heart Lung Transplant 37:385-393
Gonzalez-Nolasco, Bruno; Wang, Mengchuan; Prunevieille, Aurore et al. (2018) Emerging role of exosomes in allorecognition and allograft rejection. Curr Opin Organ Transplant 23:22-27
Smith, R N; Matsunami, M; Adam, B A et al. (2018) RNA expression profiling of nonhuman primate renal allograft rejection identifies tolerance. Am J Transplant 18:1328-1339

Showing the most recent 10 out of 305 publications